DOVER, Del. and SHANGHAI, June 1, 2018 /PRNewswire/ -- Xynomic Pharma, a clinical stage US-China oncology drug developmentcompany, today announced that it has completed Series B Crossover financing, led by experienced healthcare investors Northern Light Venture Capital, Zhongshan Bison Healthcare Investment Limited and Hakim Unique Internet Company Limited. All existing
The Series B proceeds will be used to initiate eight clinical trials, four of which are pivotal, in the next 12 months:
Xynomic has also launched its own R&D Innovation Center in Shanghai in May 2018 to discover and develop small molecule oncology drugs focused on kinase inhibition, immuno-oncology and epigenetic modification. The center is designed to have fully integrated in-house capabilities from lead identification to IND enabling studies. The first two molecules are XP-103, a TRK/Fra-1 inhibitor, and XP-104, a RET inhibitor.
About Xynomic Pharmaceuticals, Inc.Xynomic Pharmaceuticals, Inc. is a clinical stage oncology-focused biopharmaceutical company. Its lead drug candidate Abexinostat has already been tested on approximately 600 patients worldwide in 18 clinical trials, showing a more favorable safety profile among HDAC products and significant clinical benefits in patients with RCC and non-Hodgkin's lymphoma. Xynomic's pipeline also includes XP-102 (BI 882370), XP-103 and XP-104.
Media Contact: firstname.lastname@example.org
Business Development Contact: email@example.com
View original content:http://www.prnewswire.com/news-releases/xynomic-pharma-completes-series-b-crossover-financing-starts-four-pivotal-trials-in-renal-cell-carcinoma-rcc-and-lymphoma-and-opens-a-rd-center-300658004.html
SOURCE Xynomic Pharmaceuticals, Inc.
Subscribe to our Free Newsletters!